Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-614 · 3 trials · 3 indications
Blood and urine tests
Blood and urine tests
| Arm | Type | Description |
|---|---|---|
| ABT-614 | EXPERIMENTAL | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| Single Dose (Part 1) | EXPERIMENTAL | - |
| Multiple Dose (Part 2) | EXPERIMENTAL | - |
| Baseline | EXPERIMENTAL | - |
| ABT-614 Low Dose | EXPERIMENTAL | - |
| ABT-614 High Dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-614 | DRUG | Active |
| Placebo Comparator | DRUG | Placebo |
Inclusion Criteria 1. Male or female aged between 19 and 70 years, inclusive, at time of consent. 2. Type 2 diabetes receiving at least one anti-diabetic medication for at least one year at the time of Screening. 3. Hemoglobin A1c \< 12% at the time of Screening. 4. Estimated glomerular filtration ...
ABT-614 is an investigational small molecule being studied in healthy volunteers, type 2 diabetics, and patients with chronic kidney disease and protein in their urine. It has been evaluated in early-stage clinical trials for these conditions, though it is not approved for any use.
ABT-614 is being studied for its effects on D3 receptors in the brain, as evaluated in a positron emission tomography (PET) study. The drug's interaction with these receptors was the focus of an exploratory trial in healthy volunteers.
ABT-614 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT.
ABT-614 is in Phase 1 clinical development. All three completed trials for the drug were Phase 1 studies, and it remains an investigational agent not yet approved by regulatory authorities.
ABT-614 has been studied in three completed Phase 1 trials: NCT00788801, a PET study in healthy volunteers in Canada; NCT00959816, a study of drug absorption and elimination in healthy males in the United States; and NCT01464320, a safety and kidney function study in type 2 diabetics with chronic kidney disease and proteinuria.
ABT-614 is the primary name used for this investigational drug in clinical trial registrations. No alternative names have been identified in the available clinical trial data.